• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    PACS Group Announces Appointment of Evelyn Dilsaver to Serve as Independent Board Director

    5/13/24 7:31:00 PM ET
    $HQY
    $QDEL
    $TPX
    Business Services
    Consumer Discretionary
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $HQY alert in real time by email

    PACS Group, Inc. (NYSE:PACS) ("PACS" or the "Company") announced today that Evelyn Dilsaver has been appointed to serve as a member of its Board of Directors. "We're thrilled to have Evelyn join our board," said Jason Murray, PACS Chairman and CEO. "She has great experience as an accounting and finance professional, not to mention her work on the boards of several other public companies. She'll bring added perspective and expertise to the board as we work to guide PACS going forward."

    "I'm excited to join the PACS Board and assist the company in continuing its mission to provide quality skilled nursing care. I look forward to great things ahead for the company," added Ms. Dilsaver.

    Ms. Dilsaver also serves on the boards of directors of Tempur Sealy International (NYSE:TPX), HealthEquity, Inc. (NASDAQ:HQY) and QuidelOrtho (NASDAQ:QDEL). Ms. Dilsaver was President and Chief Executive Officer of Charles Schwab Investment Management from July 2004 until September 2007. Prior to that, she held various senior management positions with The Charles Schwab Corporation. Ms. Dilsaver is a certified public accountant and holds a B.S. degree in accounting from California State University-Hayward.

    Ms. Dilsaver is an independent director under applicable NYSE and SEC rules. Her appointment now makes the PACS Board of Directors majority independent. Ms. Dilsaver's committee appointments will be considered at a later date.

    About PACS Group

    PACS Group, Inc. is a holding company investing in post-acute healthcare facilities, professionals, and ancillary services. Founded in 2013, PACS Group is one of the largest post-acute platforms in the United States. Its independent subsidiaries operate over 200 post-acute care facilities across nine states serving over 20,000 patients daily.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240513694766/en/

    Get the next $HQY alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $HQY
    $QDEL
    $TPX

    CompanyDatePrice TargetRatingAnalyst
    HealthEquity Inc.
    $HQY
    5/22/2025$105.00 → $112.00Outperform
    RBC Capital Mkts
    QuidelOrtho Corporation
    $QDEL
    5/8/2025$44.00Hold → Buy
    Jefferies
    HealthEquity Inc.
    $HQY
    3/25/2025$120.00 → $115.00Outperform → Strong Buy
    Raymond James
    Tempur Sealy International Inc.
    $TPX
    2/5/2025Mkt Perform → Outperform
    William Blair
    Tempur Sealy International Inc.
    $TPX
    2/3/2025$67.00 → $80.00Neutral → Outperform
    Wedbush
    QuidelOrtho Corporation
    $QDEL
    12/11/2024$44.00 → $50.00Neutral → Buy
    Citigroup
    QuidelOrtho Corporation
    $QDEL
    12/10/2024$43.00Hold
    Jefferies
    HealthEquity Inc.
    $HQY
    12/4/2024$126.00Outperform
    Mizuho
    More analyst ratings

    $HQY
    $QDEL
    $TPX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • RBC Capital Mkts resumed coverage on HealthEquity with a new price target

      RBC Capital Mkts resumed coverage of HealthEquity with a rating of Outperform and set a new price target of $112.00 from $105.00 previously

      5/22/25 9:53:52 AM ET
      $HQY
      Business Services
      Consumer Discretionary
    • QuidelOrtho upgraded by Jefferies with a new price target

      Jefferies upgraded QuidelOrtho from Hold to Buy and set a new price target of $44.00

      5/8/25 9:44:58 AM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • HealthEquity upgraded by Raymond James with a new price target

      Raymond James upgraded HealthEquity from Outperform to Strong Buy and set a new price target of $115.00 from $120.00 previously

      3/25/25 8:22:31 AM ET
      $HQY
      Business Services
      Consumer Discretionary

    $HQY
    $QDEL
    $TPX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • QuidelOrtho Announces Strategy to Accelerate Growth in Molecular Diagnostics

      ―Company Intends to Acquire LEX Diagnostics Upon U.S. FDA Clearance――Company Plans to Discontinue Savanna® Platform Development――Company Reaffirms Full Year 2025 Financial Guidance ――Company to Host Conference Call Today at 5:00 p.m. ET― SAN DIEGO, June 3, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced a refocusing of its molecular diagnostics strategy. This strategy includes the intent to acquire full ownership of LEX Diagnostics after 510(k) clearance by the U.S. Food and Drug Administrat

      6/3/25 4:10:00 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • HealthEquity Reports First Quarter Ended April 30, 2025 Financial Results

      Highlights of the first quarter include: Revenue of $330.8 million, an increase of 15% compared to $287.6 million in Q1 FY25.Net income of $53.9 million, an increase of 87% compared to $28.8 million in Q1 FY25, with non-GAAP net income of $85.8 million, an increase of 22% compared to $70.3 million in Q1 FY25.Net income per diluted share of $0.61, an increase of 85% compared to $0.33 in Q1 FY25, with non-GAAP net income per diluted share of $0.97, an increase of 21% compared to $0.80 in Q1 FY25.Adjusted EBITDA of $140.2 million, an increase of 19% compared to $117.4 million in Q1 FY25.9.9 million HSAs, an increase of 9% compared to Q1 FY25.Total HSA Assets of $31.3 billion, an increase o

      6/3/25 4:01:00 PM ET
      $HQY
      Business Services
      Consumer Discretionary
    • QuidelOrtho to Participate in Upcoming Investor Conferences

      QuidelOrtho Corporation (NASDAQ:QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will participate in two upcoming investor conferences: William Blair 45th Annual Growth Stock Conference, Wednesday, June 4, 2025 Members of QuidelOrtho's management team will participate in a presentation at 9:00 a.m. ET / 6:00 a.m. PT. Jefferies Global Healthcare Conference, Thursday, June 5, 2025 Members of QuidelOrtho's management team will participate in a fireside chat at 8:45 a.m. ET / 5:45 a.m. PT. Interested parties can access the liv

      5/22/25 4:30:00 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $HQY
    $QDEL
    $TPX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Blaser Brian J. bought $249,878 worth of shares (6,033 units at $41.42) (SEC Form 4)

      4 - QuidelOrtho Corp (0001906324) (Issuer)

      12/13/24 4:12:57 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Busky Joseph M bought $99,663 worth of shares (2,150 units at $46.35) (SEC Form 4)

      4 - QuidelOrtho Corp (0001906324) (Issuer)

      2/26/24 6:48:23 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $HQY
    $QDEL
    $TPX
    Leadership Updates

    Live Leadership Updates

    See more
    • HealthEquity Reports Year-End Sales Metrics

      DRAPER, Utah, Feb. 18, 2025 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ:HQY) ("HealthEquity" or the "Company"), the nation's largest health savings account ("HSA") custodian, today announced its HSAs, HSA Assets and Total Accounts as of its fiscal year ended January 31, 2025. The Company also affirmed its guidance for fiscal 2025 and 2026, provided an updated HSA cash repricing schedule, and announced upcoming events and presentations. The total number of HSAs as of January 31, 2025 was 9.9 million, an increase of 14%, from 8.7 million as of January 31, 2024. The Company closed its fiscal year 2025 with 17.0 million Total Accounts, an increase of 9%, from 15.7 million as of January 31,

      2/18/25 4:01:00 PM ET
      $HQY
      Business Services
      Consumer Discretionary
    • HealthEquity Announces Record Year-End HSA Sales Outlook, Presentation at J.P. Morgan Healthcare Conference

      DRAPER, Utah, Jan. 13, 2025 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ:HQY) ("HealthEquity" or the "Company"), the nation's largest health savings account ("HSA") custodian, today announced estimates of HSAs, HSA Assets and Total Accounts for its fiscal year ending January 31, 2025, reflecting a strong sales year with record New HSAs from Sales and strong custodial HSA Asset growth. Estimated HSAs to be approximately 9.8 million by January 31, 2025, up from 8.7 million a year earlier.Estimated HSA Assets to be approximately $31 billion, up from $25.2 billion at the end of fiscal year 2024, with approximately $17 billion of HSA Cash. Invested balances included in the estimated assets a

      1/13/25 9:01:00 AM ET
      $HQY
      Business Services
      Consumer Discretionary
    • QuidelOrtho Announces Appointment of Two Independent Directors to its Board

      Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T

      12/10/24 7:00:00 AM ET
      $CTLT
      $HYPR
      $NVST
      $QDEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Medical/Dental Instruments

    $HQY
    $QDEL
    $TPX
    Financials

    Live finance-specific insights

    See more
    • QuidelOrtho Announces Strategy to Accelerate Growth in Molecular Diagnostics

      ―Company Intends to Acquire LEX Diagnostics Upon U.S. FDA Clearance――Company Plans to Discontinue Savanna® Platform Development――Company Reaffirms Full Year 2025 Financial Guidance ――Company to Host Conference Call Today at 5:00 p.m. ET― SAN DIEGO, June 3, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced a refocusing of its molecular diagnostics strategy. This strategy includes the intent to acquire full ownership of LEX Diagnostics after 510(k) clearance by the U.S. Food and Drug Administrat

      6/3/25 4:10:00 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • HealthEquity Reports First Quarter Ended April 30, 2025 Financial Results

      Highlights of the first quarter include: Revenue of $330.8 million, an increase of 15% compared to $287.6 million in Q1 FY25.Net income of $53.9 million, an increase of 87% compared to $28.8 million in Q1 FY25, with non-GAAP net income of $85.8 million, an increase of 22% compared to $70.3 million in Q1 FY25.Net income per diluted share of $0.61, an increase of 85% compared to $0.33 in Q1 FY25, with non-GAAP net income per diluted share of $0.97, an increase of 21% compared to $0.80 in Q1 FY25.Adjusted EBITDA of $140.2 million, an increase of 19% compared to $117.4 million in Q1 FY25.9.9 million HSAs, an increase of 9% compared to Q1 FY25.Total HSA Assets of $31.3 billion, an increase o

      6/3/25 4:01:00 PM ET
      $HQY
      Business Services
      Consumer Discretionary
    • HealthEquity Announces First Quarter Earnings Release Date Presentations at Investor Conferences

      DRAPER, Utah, May 09, 2025 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ:HQY) ("HealthEquity" or the "Company"), the nation's largest health savings account ("HSA") custodian, today announced plans to release its first quarter of fiscal 2026 financial results following the close of regular stock market trading hours on Tuesday, June 3, 2025. Following the news release, HealthEquity management plans to host a conference call for investors on Tuesday, June 3, 2025, at 4:30 p.m. Eastern Time during which management will review the Company's first quarter results. HealthEquity First Quarter Fiscal Year 2026 Results Conference CallDate: June 3, 2025Time:4:30 p.m. Eastern Time / 2:30 p.m. Mount

      5/9/25 4:59:50 PM ET
      $HQY
      Business Services
      Consumer Discretionary

    $HQY
    $QDEL
    $TPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Legal Officer Hodges Michelle A was granted 11,873 shares and covered exercise/tax liability with 6,030 shares, increasing direct ownership by 25% to 29,212 units (SEC Form 4)

      4 - QuidelOrtho Corp (0001906324) (Issuer)

      7/2/25 4:10:58 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chief Financial Officer Busky Joseph M. was granted 21,367 shares and covered exercise/tax liability with 9,883 shares, increasing direct ownership by 58% to 31,427 units (SEC Form 4)

      4 - QuidelOrtho Corp (0001906324) (Issuer)

      7/2/25 4:08:51 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chief Operations Officer Mclellan Philip D. was granted 4,749 shares and covered exercise/tax liability with 1,951 shares, increasing direct ownership by 27% to 13,304 units (SEC Form 4)

      4 - QuidelOrtho Corp (0001906324) (Issuer)

      7/2/25 4:06:41 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $HQY
    $QDEL
    $TPX
    SEC Filings

    See more
    • SEC Form S-8 filed by QuidelOrtho Corporation

      S-8 - QuidelOrtho Corp (0001906324) (Filer)

      6/27/25 9:17:36 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • HealthEquity Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - HEALTHEQUITY, INC. (0001428336) (Filer)

      6/27/25 4:02:48 PM ET
      $HQY
      Business Services
      Consumer Discretionary
    • SEC Form 10-Q filed by HealthEquity Inc.

      10-Q - HEALTHEQUITY, INC. (0001428336) (Filer)

      6/3/25 4:05:08 PM ET
      $HQY
      Business Services
      Consumer Discretionary

    $HQY
    $QDEL
    $TPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by QuidelOrtho Corporation

      SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)

      12/6/24 10:11:24 AM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13D/A filed by QuidelOrtho Corporation

      SC 13D/A - QuidelOrtho Corp (0001906324) (Subject)

      11/21/24 5:10:19 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13G/A filed by QuidelOrtho Corporation

      SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)

      11/14/24 1:28:35 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care